Mar 14, 2023
Featuring perspectives from Dr Christopher Lieu, including the following topics:
• Early-Onset Colorectal Cancer
o Introduction (00:00)
• Localized Disease
o Case: A woman in her mid 30s with left-sided T3N0 Grade II obstructing adenocarcinoma of the colon — William R Mitchell, MD (16:31)
o Case: A woman in her early 50s with Stage II mismatch repair-proficient sigmoid colon cancer with focal intramural lymphovascular invasion after 6 cycles of adjuvant capecitabine — Priya Rudolph, MD, PhD (19:51)
• Metastatic Disease
o Case: A woman in her mid 80s with pan-RAS wild-type (WT) metastatic rectal cancer with poor tolerance to chemotherapy, now receiving regorafenib with slowly progressive disease — Eric H Lee, MD, PhD (32:09)
o Case: A man in his early 60s with recurrent, microsatellite stable, HER2-negative, RAS WT rectal cancer, currently receiving TAS-102/bevacizumab — Swati Vishwanathan, MD (35:16)
• HER2-Positive Disease
o Case: A woman in her mid 50s with RAS WT, HER2-amplified metastatic colon adenocarcinoma — Gigi Chen, MD (44:38)
o Case: A woman in her mid 60s with multiregimen-relapsed RAS WT, HER2-positive metastatic rectal cancer, now receiving trastuzumab/tucatinib — Sunil Gandhi, MD (50:47)
• Microsatellite Instability-High Disease; BRAF-Mutant Disease
o Case: A woman in her late 70s with HER2-negative, BRAF V600E-mutant, microsatellite stable metastatic colon cancer after mFOLFOX/bevacizumab followed by maintenance 5-FU/bevacizumab — Victoria Giffi, MD (58:14)